Cargando…

Development of oral candidiasis following initiation and rechallenge of extended-release bupropion in a geriatric patient

OBJECTIVE: To report a case of oral candidiasis that developed in a 70-year-old white female both upon initiation and rechallenge of extended-release bupropion therapy. CASE SUMMARY: A 70-year-old female with a past medical history of osteoarthritis, degenerative joint disease, and polycythemia vera...

Descripción completa

Detalles Bibliográficos
Autores principales: Vadiei, Nina, Smith, Tawny L., Garcia-Pittman, Erica C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: College of Psychiatric & Neurologic Pharmacists 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063460/
https://www.ncbi.nlm.nih.gov/pubmed/30155394
http://dx.doi.org/10.9740/mhc.2018.07.188
_version_ 1783342562327658496
author Vadiei, Nina
Smith, Tawny L.
Garcia-Pittman, Erica C.
author_facet Vadiei, Nina
Smith, Tawny L.
Garcia-Pittman, Erica C.
author_sort Vadiei, Nina
collection PubMed
description OBJECTIVE: To report a case of oral candidiasis that developed in a 70-year-old white female both upon initiation and rechallenge of extended-release bupropion therapy. CASE SUMMARY: A 70-year-old female with a past medical history of osteoarthritis, degenerative joint disease, and polycythemia vera developed oral candidiasis on 2 occasions following initiation of extended-release bupropion for the treatment of recurrent depression. During both instances, the reaction occurred with an increased dose of the medication, suggesting the adverse event may have been dose-related. The patient had no risk factors for oral candidiasis aside from dry mouth at baseline that reportedly worsened on bupropion. DISCUSSION: Though there are no other reports to our knowledge describing the development of oral candidiasis with bupropion, the likelihood of this having been an adverse reaction in this patient is probable as indicated by a calculated score of 8 from the Naranjo Algorithm. The adverse event appeared following bupropion administration and improved over time following its discontinuation. The adverse event reappeared following readministration of the agent, and no alternative causes were able to be identified. Additionally, the reaction occurred following an increase in the dose on both occasions, with the lower dose having only resulted in worsening dry mouth. CONCLUSION: This case demonstrates that an additional adverse event to screen for with bupropion treatment is the development of oral candidiasis. This adverse event may be more likely to occur in the older adult population.
format Online
Article
Text
id pubmed-6063460
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher College of Psychiatric & Neurologic Pharmacists
record_format MEDLINE/PubMed
spelling pubmed-60634602018-08-28 Development of oral candidiasis following initiation and rechallenge of extended-release bupropion in a geriatric patient Vadiei, Nina Smith, Tawny L. Garcia-Pittman, Erica C. Ment Health Clin Case Reports OBJECTIVE: To report a case of oral candidiasis that developed in a 70-year-old white female both upon initiation and rechallenge of extended-release bupropion therapy. CASE SUMMARY: A 70-year-old female with a past medical history of osteoarthritis, degenerative joint disease, and polycythemia vera developed oral candidiasis on 2 occasions following initiation of extended-release bupropion for the treatment of recurrent depression. During both instances, the reaction occurred with an increased dose of the medication, suggesting the adverse event may have been dose-related. The patient had no risk factors for oral candidiasis aside from dry mouth at baseline that reportedly worsened on bupropion. DISCUSSION: Though there are no other reports to our knowledge describing the development of oral candidiasis with bupropion, the likelihood of this having been an adverse reaction in this patient is probable as indicated by a calculated score of 8 from the Naranjo Algorithm. The adverse event appeared following bupropion administration and improved over time following its discontinuation. The adverse event reappeared following readministration of the agent, and no alternative causes were able to be identified. Additionally, the reaction occurred following an increase in the dose on both occasions, with the lower dose having only resulted in worsening dry mouth. CONCLUSION: This case demonstrates that an additional adverse event to screen for with bupropion treatment is the development of oral candidiasis. This adverse event may be more likely to occur in the older adult population. College of Psychiatric & Neurologic Pharmacists 2018-06-29 /pmc/articles/PMC6063460/ /pubmed/30155394 http://dx.doi.org/10.9740/mhc.2018.07.188 Text en © 2018 CPNP. http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Vadiei, Nina
Smith, Tawny L.
Garcia-Pittman, Erica C.
Development of oral candidiasis following initiation and rechallenge of extended-release bupropion in a geriatric patient
title Development of oral candidiasis following initiation and rechallenge of extended-release bupropion in a geriatric patient
title_full Development of oral candidiasis following initiation and rechallenge of extended-release bupropion in a geriatric patient
title_fullStr Development of oral candidiasis following initiation and rechallenge of extended-release bupropion in a geriatric patient
title_full_unstemmed Development of oral candidiasis following initiation and rechallenge of extended-release bupropion in a geriatric patient
title_short Development of oral candidiasis following initiation and rechallenge of extended-release bupropion in a geriatric patient
title_sort development of oral candidiasis following initiation and rechallenge of extended-release bupropion in a geriatric patient
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6063460/
https://www.ncbi.nlm.nih.gov/pubmed/30155394
http://dx.doi.org/10.9740/mhc.2018.07.188
work_keys_str_mv AT vadieinina developmentoforalcandidiasisfollowinginitiationandrechallengeofextendedreleasebupropioninageriatricpatient
AT smithtawnyl developmentoforalcandidiasisfollowinginitiationandrechallengeofextendedreleasebupropioninageriatricpatient
AT garciapittmanericac developmentoforalcandidiasisfollowinginitiationandrechallengeofextendedreleasebupropioninageriatricpatient